Literature DB >> 21321169

Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care.

Shelley Pallan1, Aliya Khan.   

Abstract

Objective To discuss the presentation, diagnosis, and management of primary hyperparathyroidism (PHPT) in family medicine. Quality of evidence MEDLINE was searched from 2002 to 2009 using the terms presentation, diagnosis, and treatment of PHPT. Proceedings and guidelines from the Third International Workshop on Primary Hyperparathyroidism in May 2008 were reviewed in detail. Most studies offered level II and III evidence, although there were a number of single randomized controlled trials on PHPT (level I evidence). References from pertinent papers were also searched for relevant articles. Articles most relevant to family medicine and primary care practitioners are presented. Main message Primary hyperparathyroidism is the most common cause of hypercalcemia in outpatients. In the Western world, most patients with PHPT present with nonspecific symptoms such as fatigue, mood disturbances, and cognitive impairments. Diagnosis is established when intact parathyroid hormone levels are elevated or at the high end of the normal range in the setting of elevated total or ionized calcium levels (following exclusion of conditions that can mimic PHPT). Criteria for surgery have recently been modified. Surgery is always a suitable option in those with symptomatic PHPT and no contraindications. Those with contraindications or with asymptomatic PHPT not meeting the criteria for surgery can generally be safely monitored and considered for medical management. This might include treatment with bisphosphonates, hormone replacement therapy, raloxifene, or calcimimetic agents; however, there are currently no fracture data for any of these options. Conclusion The definitive therapy for symptomatic and asymptomatic PHPT is parathyroidectomy. In patients with asymptomatic PHPT not meeting the criteria for surgery, monitoring is safe and medical management designed to target skeletal protection or lower serum calcium is a suitable option.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321169      PMCID: PMC3038812     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  37 in total

Review 1.  Primary hyperparathyroidism: pathophysiology and impact on bone.

Authors:  A Khan; J Bilezikian
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

2.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

3.  Therapeutic radiation and hyperparathyroidism. A case-control study in Rochester, Minn.

Authors:  C M Beard; H Heath; W M O'Fallon; J A Anderson; J D Earle; L J Melton
Journal:  Arch Intern Med       Date:  1989-08

4.  Primary hyperparathyroidism: King Khalid University Hospital Experience.

Authors:  M A Fouda
Journal:  Ann Saudi Med       Date:  1999 Mar-Apr       Impact factor: 1.526

5.  Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas.

Authors:  B T Teh; F Farnebo; U Kristoffersson; B Sundelin; J Cardinal; R Axelson; A Yap; M Epstein; H Heath; D Cameron; C Larsson
Journal:  J Clin Endocrinol Metab       Date:  1996-12       Impact factor: 5.958

Review 6.  A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003.

Authors:  James M Ruda; Christopher S Hollenbeak; Brendan C Stack
Journal:  Otolaryngol Head Neck Surg       Date:  2005-03       Impact factor: 3.497

7.  Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Authors:  Aliya A Khan; John P Bilezikian; Annie W C Kung; Mustafa M Ahmed; Sacha J Dubois; Andrew Y Y Ho; Debra Schussheim; Mishaela R Rubin; Atif M Shaikh; Shonni J Silverberg; Timothy I Standish; Zareen Syed; Zeba A Syed
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

8.  Devastating skeletal effects of delayed diagnosis of complicated primary hyperparathyroidism because of ectopic adenoma.

Authors:  Enio Ricardo Vasconcelos Souza; Juliana Alves Scrignoli; Fabiane Castilho Bezerra; Sandra Lúcia Euzébio Ribeiro; Luiz Fernando de Souza Passos
Journal:  J Clin Rheumatol       Date:  2008-10       Impact factor: 3.517

9.  Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial.

Authors:  Jens Bollerslev; Svante Jansson; Charlotte L Mollerup; Jörgen Nordenström; Eva Lundgren; Ove Tørring; Jan-Erik Varhaug; Marek Baranowski; Sylvi Aanderud; Celina Franco; Bo Freyschuss; Gunhild A Isaksen; Thor Ueland; Thord Rosen
Journal:  J Clin Endocrinol Metab       Date:  2007-02-06       Impact factor: 5.958

10.  Asymptomatic primary hyperparathyroidism: standards and guidelines for diagnosis and management in Canada: Consensus Development Task Force on Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism position paper.

Authors: 
Journal:  Endocr Pract       Date:  2003 Sep-Oct       Impact factor: 3.443

View more
  16 in total

1.  Bilateral pathologic mid-tibial stress fractures: Initial presentation of mild primary hyperparathyroidism.

Authors:  Fahim Merali; Mark Leung
Journal:  Can Fam Physician       Date:  2017-08       Impact factor: 3.275

2.  Same-day discharge after unilateral parathyroidectomy is safe.

Authors:  John K Peel; Adrienne L Melck
Journal:  Can J Surg       Date:  2016-08       Impact factor: 2.089

3.  Bilateral femoral fractures in a 21-year-old man following a simple fall.

Authors:  Rachel French; Deyana Oweis; Vijay Kurup
Journal:  BMJ Case Rep       Date:  2013-09-07

4.  Diagnostic value of endoscopic ultrasonography for preoperative localization of parathyroid adenomas.

Authors:  Reyhan Ersoy; Osman Ersoy; Berna Evranos Ogmen; Sefika Burcak Polat; Mehmet Kilic; Nilufer Yildirim; Levent Ozturk; Bekir Cakir
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

Review 5.  Primary hyperparathyroidism.

Authors:  Tarıq Madkhali; Amal Alhefdhi; Herbert Chen; Dawn Elfenbein
Journal:  Ulus Cerrahi Derg       Date:  2016-03-01

Review 6.  Parathyroid Pathology.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Surg Pathol Clin       Date:  2019-09-27

7.  Multiple fractures in a 22-year-old man after a simple fall.

Authors:  Mohammed H Alattas; Ronald Dimentberg
Journal:  J Surg Case Rep       Date:  2015-10-01

Review 8.  Denosumab: mechanism of action and clinical outcomes.

Authors:  D A Hanley; J D Adachi; A Bell; V Brown
Journal:  Int J Clin Pract       Date:  2012-09-12       Impact factor: 2.503

9.  Evidence based solving approach in diagnosis of primary hyperparathyroidism with oral manifestations: report of three unusual cases.

Authors:  Ruchi Bindal; Ajay Kumar; Harkanwal Preet Singh; Sanjiv Kumar Bansal; Aadya Sharma
Journal:  J Lab Physicians       Date:  2013-07

10.  Finger Fractures as an Early Manifestation of Primary Hyperparathyroidism Among Young Patients: A Case Report of a 30-Year-Old Male With Recurrent Osteoporotic Fractures.

Authors:  Akihiko Ozaki; Tetsuya Tanimoto; Eiki Yamagishi; Shunsuke Sato; Manabu Tsukada; Toyoaki Sawano; Claire Leppold; Kenji Tsuda; Takanori Asakura; Masaharu Tsubokura; Shigeaki Kato; Masahiro Kami; Hiromichi Ohira
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.